Oxford Biodynamics could triple its revenue

Oxford Biodynamics could triple its revenue

Oxford Biodynamics' (OBD) shares have moved sideways since mid-2018, trading roughly a quarter short of the 279p peak seen in October 2017. The stock didn’t react strongly to these final numbers either, even though demand for the group’s proprietary biotechnology platform, EpiSwitch, kept annual revenues flat, while a recent £9.8m investment from GL Capital has bolstered the cash coffers to £18m (FY2017: £10.8m).

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now